NTRA Strangle Strategy
NTRA (Natera, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.
NTRA (Natera, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $27.97B, a beta of 1.57 versus the broader market, a 52-week range of 131.811-256.36, average daily share volume of 1.3M, a public-listing history dating back to 2015, approximately 4K full-time employees. These structural characteristics shape how NTRA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.57 indicates NTRA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on NTRA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current NTRA snapshot
As of May 15, 2026, spot at $189.07, ATM IV 50.00%, IV rank 21.83%, expected move 14.33%. The strangle on NTRA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on NTRA specifically: NTRA IV at 50.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a NTRA strangle, with a market-implied 1-standard-deviation move of approximately 14.33% (roughly $27.10 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NTRA expiries trade a higher absolute premium for lower per-day decay. Position sizing on NTRA should anchor to the underlying notional of $189.07 per share and to the trader's directional view on NTRA stock.
NTRA strangle setup
The NTRA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NTRA near $189.07, the first option leg uses a $200.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NTRA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NTRA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $200.00 | $6.95 |
| Buy 1 | Put | $180.00 | $7.05 |
NTRA strangle risk and reward
- Net Premium / Debit
- -$1,400.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$1,400.00
- Breakeven(s)
- $166.00, $214.00
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NTRA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NTRA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$16,599.00 |
| $41.81 | -77.9% | +$12,418.67 |
| $83.62 | -55.8% | +$8,238.34 |
| $125.42 | -33.7% | +$4,058.01 |
| $167.22 | -11.6% | -$122.33 |
| $209.03 | +10.6% | -$497.34 |
| $250.83 | +32.7% | +$3,682.99 |
| $292.63 | +54.8% | +$7,863.32 |
| $334.44 | +76.9% | +$12,043.65 |
| $376.24 | +99.0% | +$16,223.98 |
When traders use strangle on NTRA
Strangles on NTRA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NTRA chain.
NTRA thesis for this strangle
The market-implied 1-standard-deviation range for NTRA extends from approximately $161.97 on the downside to $216.17 on the upside. A NTRA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NTRA IV rank near 21.83% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NTRA at 50.00%. As a Healthcare name, NTRA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NTRA-specific events.
NTRA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NTRA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NTRA alongside the broader basket even when NTRA-specific fundamentals are unchanged. Always rebuild the position from current NTRA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NTRA?
- A strangle on NTRA is the strangle strategy applied to NTRA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NTRA stock trading near $189.07, the strikes shown on this page are snapped to the nearest listed NTRA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NTRA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NTRA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 50.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,400.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NTRA strangle?
- The breakeven for the NTRA strangle priced on this page is roughly $166.00 and $214.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NTRA market-implied 1-standard-deviation expected move is approximately 14.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NTRA?
- Strangles on NTRA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NTRA chain.
- How does current NTRA implied volatility affect this strangle?
- NTRA ATM IV is at 50.00% with IV rank near 21.83%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.